Biotechnology
Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor
NANJING, China, Sept. 2, 2024 /PRNewswire/ -- On September 02, 2024, Simcere Zaiming, an innovative oncology company under Simcere Pharmaceutical Group (2096.HK), announced a collaboration agreement with Shenzhen TargetRx Inc. The partnership focuses on the ALK/ROS1 dual receptor tyrosine kinase ...
Frost & Sullivan Released Report: "BiBo Pharma: A Global CDMO Leading in Advanced Biopharmaceutical Manufacturing Technologies"
SHANGHAI, Sept. 2, 2024 /PRNewswire/ -- Frost & Sullivan released a report, titled "BiBo Pharma: A Global CDMO Leading in Advanced Biopharmaceutical Manufacturing Technologies". The report explores a global CDMO leading the "The Fourth Revolutionary Wave of Biologics Manufacturing" and pioneering...
ThinkCyte Secures $32 million in Series C Funding to Drive Global Expansion of VisionSort™
TOKYO and REDWOOD CITY, Calif., Aug. 31, 2024 /PRNewswire/ -- ThinkCyte today announced the successful completion of its Series C funding round. Including the equity financingsecured last November, the company raised an additional $15 million in the extension round, bringing the total to $32 mill...
Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China
BEIJING and SHANGHAI and BOSTON, Aug. 30, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that it has granted theChina rights (including mainland China, Hong Kong, Macau, and Taiwan) of KRAS G12C inhibitor glecirasi...
Breaking News | Sanyou Bio Launches Comprehensive Monkeypox Product Line
SHANGHAI, Aug. 30, 2024 /PRNewswire/ -- On August 28, 2024, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. announced the launch of a comprehensive product line targeting monkeypox, which includes antigens, monoclonal antibodies, and overexpression cell lines. This product line features 65 items ...
/DISREGARD RELEASE: Celltrion USA/
We are advised by Celltrion USA that journalists and other readers should disregard the news release, CelltrionUSA partners with Express Scripts and Cigna Healthcare to expand access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab on their medical benefit ...
Unlock the Full Potential of Cell and Gene Therapies: The 2024 GenScript Biotech Global Forum Heads to London
PISCATAWAY, N.J., Aug. 29, 2024 /PRNewswire/ -- The cell and gene therapy (CGT) industry has witnessed remarkable growth in recent years. According to an analysis by RSM US LLP, CGT therapies accounted for 10% of all FDA-approved drugs last year, with the number of approvals anticipated to contin...
CARsgen® Announces 2024 Interim Results
SHANGHAI, Aug. 29, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, has announced its 2024 Interim Results. Business Highlights * Zevor-cel was...
Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms
Results Highlights for Interim Results ended 30 June 2024 Revenue reached RMB981.8 million Gross profit amounted to RMB339.1 million Net profit grew by 956.0 YoY to RMB144.2 million Adjusted non-IFRS net profit reached RMB168.2 million, increased by 15.1% YoY HONG KONG, Aug. 29, 2024 /PRNewswire/ ...
Transcenta Holding Limited (Stock Code: 6628.HK) Announce 2024 Interim Results
2024 Interim Result Highlights (For the six months ended June 30, 2024) * Company published the efficacy and safety data of Cohort-G of TranStar102 study for osemitamab (TST001), plus checkpoint inhibitor and CAPOX as the first-line treatment of patients with locally advanced or metastatic G/GE...
Biocon Biologics Secures Market Entry for Bmab 1200, a Proposed Biosimilar to Stelara®, in Europe, UK, Canada, and Japan
BENGALURU, India, Aug. 29, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the Company has signed a settlement and license agreement with Janssen Biotech Inc., Janss...
LOTTE Holdings establishes a new Healthcare and Biopharmaceutical Corporate Venture Capital
TOKYO, Aug. 29, 2024 /PRNewswire/ -- LOTTE Holdings Co., Ltd. ("LOTTE
Holdings") is pleased to announce the establishment of a new Healthcare and
Biopharmaceutical Corporate Venture Capital ("CVC") dedicated to investing in
biopharmaceuticals and next-generation modalities.
Innovent to Present Clinical Data of Multiple Novel Molecules at WCLC and ESMO 2024
SAN FRANCISCO and SUZHOU, China, Aug. 29, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
Akeso's 2024 First Half Interim Results: Expanding Global Lead in IO Bispecific Antibodies, Advancing New Therapies, and Accelerating Commercialization
* Approval of ivonescimab for 2L+ EGFRm NSCL; HARMONi-A is the only phase III study that demonstrates significant benefit across all subgroups for PFS, and is also the only study to achieve the primary endpoint while showing a positive trend in OS benefit; HARMONi-A study presented in an oral p...
Innovent Announces 2024 Interim Results and Business Updates
Strong commercial performance and significant pipeline milestones support sustained growth and innovation SAN FRANSISCO and SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and com...
Tigermed Reports 2024 Interim Results
HANGZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its int...
Fosun Pharma Announces 2024 Interim Results
Breakthroughs for Innovative Products Going Overseas with Global Operation Capabilities Continuing to Strengthen SHANGHAI, Aug. 28, 2024 /PRNewswire/ -- On August 27, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH; 02196.HK), announced its o...
Harbour BioMed Announces 2024 Interim Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology an...
Achieva Medical Entered into an Exclusive Distribution Agreement with NowYon Medical
SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its wholly-owned subsidiary, Achieva Medical Limited ("Achieva Medical"), entered ...
Unique International Collaboration Brings Breakthrough Oral Cholera Vaccine to Market
Singapore-based Hilleman Laboratories, along with Bharat Biotech, confirm launch of new cholera vaccine, HILLCHOL® Success provides "template for the internationalization of future vaccine and biologics development fromSingapore" – Dr. Raman Rao, CEO, Hilleman Laboratories Hilleman Laboratories ...
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00